VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial. It has strategic collaboration agreements with Shanghai Pharmaceutical, XtalPi, Anke Bio, and the United Family Healthcare. VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China. Address: Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, China